Naslov
Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomized trial.

Autori
White, H.D. ; Simes, R.J. ; Aylward, P.E.G. ; Armstrong, P.W. ; Califf, R.M. ; French, J.K. ; Granger, C.B. ; Marschner, I.C. ; Topol, E.J. ; Van de Werf, F.J. ; Wilcox, R.G.

Izvornik
Lancet (0140-6736) 358 (2001), 9296; 1855-1863

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
acute myocardial infarction; treatment; bivalirudin

Sažetak
The combination of fibrinolytic therapy and heparin for acute myocardial infarction fails to achieve reperfusion in 40-70% of patients, and early reocclusion occurs in a substantial number. We did a randomised, open-label trial to compare the thrombin-specific anticoagulant, bivalirudin, with heparin in patients undergoing fibrinolysis with streptokinase for acute myocardial infarction. Bivalirudin did not reduce mortality compared with unfractionated heparin, but did reduce the rate of adjudicated reinfarction within 96 h by 30%. Small absolute increases were seen in mild and moderate bleeding in patients given bivalirudin. Bivalirudin is a new anticoagulant treatment option in patients with acute myocardial infarction treated with streptokinase.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA